Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis. METHODS: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The components of the primary end point and safety were also assessed. RESULTS: A total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine group, and 2379 to the placebo group. Patients were followed for a median of 22.6 months. The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization. Diarrhea was reported in 9.7% of the patients in the colchicine group and in 8.9% of those in the placebo group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03). CONCLUSIONS: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trials have shown that targeted inhibition of this inflammatory pathway, as measured by changes in CRP concentrations, can reduce the rate of cardiovascular events.5, 6, 7”
From Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This was also not an isolated finding as a similar reduction of CVD risk linked to reduction of inflammation was reported in the COLCOT trial when participants were given low‐dose colchicine (a standard anti‐inflammatory drug) (Tardif et al., 2019).”
From Treatment of periodontitis and C ‐reactive protein: A systematic review and meta‐analysis of randomized clinical trials (2023) · cites this paper as Tardif et al., 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“However, when appraised together, the evidence supports apolipoprotein B as being necessary for lipid-mediated atherogenesis by LDL-C to occur. 57,58 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [58]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain
Ravelli, R. B. G., Gigant, B., Curmi, P. A., Jourdain, I., Lachkar, S., Sobel, A., & Knossow, M. (2004) · Nature · doi:10.1038/nature02393 · Cited by 1,630
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Self-citationLow-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.027 · Cited by 1,054
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Imazio, M., Bobbio, M., Cecchi, E., Demarie, D., Demichelis, B., Pomari, F., Moratti, M., Gaschino, G., Giammaria, M., Ghisio, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.542738 · Cited by 614
Cited by
Items 801–900 of 1,006
Timmerman, N., Waissi, F., Dekker, M., de Borst, G. J., van Bennekom, J., de Winter, R. J., Hilvo, M., Jylhä, A., Pasterkamp, G., de Kleijn, D. P. V., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09225-6 · Cited by 27
Anti-Inflammatory Drug Candidates for Prevention and Treatment of Cardiovascular Diseases
Delbaere, Q., Chapet, N., Huet, F., Delmas, C., Mewton, N., Prunier, F., Angoulvant, D., & Roubille, F. (2023) · Pharmaceuticals · doi:10.3390/ph16010078 · Cited by 31
Self-citationDihoum, A., Rena, G., Pearson, E. R., Lang, C. C., & Mordi, I. R. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2196010 · Cited by 33
Stroes, E. S. G., Bays, H. E., Banach, M., Catapano, A. L., Duell, P. B., Laufs, U., Mancini, G. B. J., Ray, K. K., Sasiela, W. J., Zhang, Y., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.020 · Cited by 29
Buonpane, A., Trimarchi, G., Ciardetti, M., Coceani, M. A., Alagna, G., Benedetti, G., Berti, S. L., Andò, G., Burzotta, F., & Caterina, A. R. D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13195791 · Cited by 29
“The COLCOT trial [173] and LoDoCo2 trial [174] have demonstrated the efficacy of colchicine in reducing CV events in ACS and stable CAD patients already receiving full standard-of-care treatment, including high-dose statins.”
MethodRole of Heat Shock Protein 27 in Modulating Atherosclerotic Inflammation
Inia, J. A., & O’Brien, E. R. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10000-z · Cited by 26
“Although some [22, 23] but not all [24, 25] recent pre-clinical and clinical trials support the anti-inflammation approach for the treatment of atherosclerosis, CANTOS stands out as an intriguing proof-of-concept trial that highlights the need for additional anti-inflammatory studies.”
Favalli, E. G., Maioli, G., & Caporali, R. F. (2024) · Drugs · doi:10.1007/s40265-024-02059-8 · Cited by 32
“Recently, large RCTs have shown that modulation of inflammation could be an effective prevention strategy in the general population [99, 100] as well as in RA patients.”
Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review
Zubirán, R., Neufeld, E. B., Dasseux, A., Remaley, A. T., & Sorokin, A. V. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00376-3 · Cited by 33
“More recently, the LODOCO2 [98] and the COLCOT [99] studies demonstrated the utility of low-dose colchicine to reduce the risk of recurrent ischemic CV events.”
BackgroundA new clinical age of aging research
Zhang, Z., Yang, R., Zi, Z., & Liu, B. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.08.004 · Cited by 28
Neuroimmune cross-talk in heart failure
Montuoro, S., Gentile, F., & Giannoni, A. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae236 · Cited by 28
Precision Medicine for Cardiovascular Prevention and Population Health: A Bridge Too Far?
Giugni, F., Berry, J. D., Khera, A., Shah, A. M., & de Lemos, J. A. (2024) · Circulation · doi:10.1161/circulationaha.124.070081 · Cited by 26
Kraaijenhof, J. M., Kerkvliet, M., Nurmohamed, N. S., Grefhorst, A., Kroon, J., Wareham, N. J., Hovingh, G. K., Stroes, E. S. G., Boekholdt, S. M., & Reeskamp, L. F. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf037 · Cited by 33
Cholesterol Crystals as Triggers of NLRP3 Inflammasome Activation in Atherosclerosis
Yalçınkaya, M., & Tall, A. R. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01323-w · Cited by 35
“Although recent trials of anti-inflammatory therapies [7, 9, 10] have shown amelioration of ASCVD, these approaches also led to more infections and have not been widely adopted, which emphasise the need for more detailed understanding of cellular and molecular mechanisms of inflammatory responses…”
IRF5 siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis
He, Z., Luo, Y., Duan, Z., Su, B., Zeng, W., Guo, Y., Li, Y., He, X., Shi, H., Zhou, Z., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.075352 · Cited by 32
Beyond the lung involvement in COVID-19 patients
Tuttolomondo, D., Frizzelli, A., Aiello, M., Bertorelli, G., Majori, M., & Chetta, A. A. (2021) · Minerva Medica · doi:10.23736/s0026-4806.20.06719-1 · Cited by 27
Mansouri, N., Marjani, M., Tabarsi, P., von Garnier, C., & Mansouri, D. (2020) · Immunological Investigations · doi:10.1080/08820139.2020.1789655 · Cited by 24
“fever (FMF), pericarditis, prevention of recurrent cardiac events, and other autoinflammatory disorders (El Hasbani et al. 2019; Imazio et al. 2013; Ostrov 2015; Pascart and Richette 2018; Tardif et al. 2019).”
BackgroundSpray, L., Park, C., Cormack, S., Mohammed, A., Panahi, P., Boag, S. E., Bennaceur, K., Sopova, K., Richardson, G. D., Stangl, V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.605857 · Cited by 26
Kaveh, A., Bruton, F. A., Oremek, M. E. M., Tucker, C. S., Taylor, J. M., Mullins, J. J., Rossi, A. G., & Denvir, M. A. (2021) · Development · doi:10.1242/dev.199636 · Cited by 26
“Recent clinical trials have investigated immunomodulatory therapies that inhibit pleiotropic inflammatory pathways (Ridker et al., 2017 and Tardif et al., 2019).”
BackgroundEmerging Anti-Atherosclerotic Therapies
Gluba-Brzózka, A., Franczyk, B., Rysz-Górzyńska, M., Ławiński, J., & Rysz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212109 · Cited by 30
“The therapy with colchicine was also found to reduce the risk of cardiovascular events, such as angina, myocardial infarction, and death [77].”
BackgroundTherapeutic role of immunomodulators during the COVID-19 pandemic– a narrative review
Alhajeri, H., Baron, F., Abutiban, F., Mutairi, M. A., Ali, Y., Al-Awadhi, A. M., Albasri, A., Aldei, A., Alenizi, A., Alhadhood, N., et al. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2033563 · Cited by 25
Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons
Torzewski, J., Brunner, P., Ries, W., Garlichs, C. D., Kayser, S., Heigl, F., & Sheriff, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071771 · Cited by 26
Macrophages in Atheromatous Plaque Developmental Stages
von Ehr, A., Bode, C., & Hilgendorf, I. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.865367 · Cited by 24
Aulin, J., Hijazi, Z., Lindbäck, J., Alexander, J. H., Gersh, B. J., Granger, C. B., Hanna, M., Horowitz, J. D., Lópes, R. D., McMurray, J. J. V., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.03.009 · Cited by 24
Somatic Mutations and Clonal Hematopoiesis as Drivers of Age-Related Cardiovascular Risk
Haring, B., Wissel, S., & Manson, J. E. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01724-2 · Cited by 31
Colchicine for Cardiovascular Medicine: A Systematic Review and meta-analysis
Casula, M., Andreis, A., Avondo, S., Vaira, M. P., & Imazio, M. (2022) · Future Cardiology · doi:10.2217/fca-2020-0206 · Cited by 26
Heparanase: A Novel Therapeutic Target for the Treatment of Atherosclerosis
Nguyen, T. K., Paone, S., Chan, E., Poon, I. K. H., Baxter, A. A., Thomas, S. R., & Hulett, M. D. (2022) · Cells · doi:10.3390/cells11203198 · Cited by 27
“For example, the CANTOS and COLCOT trials recently reported that treatment of high-risk CAD patients with a neutralising antibody to IL-1b (Canakinumab) or anti-inflammatory drug colchicine reduced the incidence of recurrent cardiovascular events [76,77].”
Result“Vascular inflammation and cardiovascular disease: review about the role of PET imaging”
Sammartino, A. M., Falco, R., Drera, A., Dondi, F., Bellini, P., Bertagna, F., & Vizzardi, E. (2022) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-022-02730-9 · Cited by 27
“CANTOS [52] and COLCOT [53] trials demonstrated respectively that canakinumab (monoclonal antibody targeting interleukin-1β) and colchicine led to a significantly lower rate and lower risk of cardiovascular events.”
BackgroundClinical and Coronary Plaque Predictors of Atherosclerotic Nonresponse to Statin Therapy
Rosendael, S. E. V., van den Hoogen, I. J., Lin, F. Y.-H., Andreini, D., Al-Mallah, M. H., Budoff, M. J., Cademartiri, F., Chinnaiyan, K. M., Choi, J. H., Conte, E., et al. (2022) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2022.10.017 · Cited by 29
Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence
Cimmino, G., Loffredo, F. S., Rosa, G. D., & Cirillo, P. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032483 · Cited by 25
An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk
Mohammadnia, N., Opstal, T. S. J., Messaoudi, S. E., Bax, W. A., & Cornel, J. H. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.08.016 · Cited by 30
Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology
Thackeray, J. T., Lavine, K. J., & Liu, Y. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264865 · Cited by 24
Li, H., Yang, H., Qin, Z., Wang, Q., & Li, L. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03697-8 · Cited by 32
“Clinical studies have found that colchicine has potential benefits in the secondary prevention of coronary artery disease and the stabilization of coronary plaque [21, 41–43].”
BackgroundShchendrygina, A., Rachina, S. A., Cherkasova, N., Suvorov, А. Y., Komarova, I. S., Mukhina, N., Ananicheva, N., Gasanova, D., Sitnikova, V., Koposova, A. O., et al. (2023) · Open Heart · doi:10.1136/openhrt-2023-002360 · Cited by 32
Liao, J., Qiu, M., Su, X., Qi, Z., Xu, Y., Liu, H., Xu, K., Wang, X., Li, J., Li, Y., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02156-3 · Cited by 28
“Moreover, large-scale randomized controlled studies have indicated that colchicine not only decreases ischemic events by 23% in recent MI patients but also reduces cardiovascular event risk by one-third among individuals with chronic coronary heart disease receiving standard therapy [30, 31].”
BackgroundPan, Y., Fan, F., Jiang, J., & Zhang, Y. (2025) · Inflammation Research · doi:10.1007/s00011-025-02058-9 · Cited by 27
Rabbani, A. B., Parikh, R. V., & Rafique, A. M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13556 · Cited by 26
Klooster, C. C. V. ’., Bhatt, D. L., Steg, P. G., Massaro, J. M., Dorresteijn, J. A. N., Westerink, J., Ruigrok, Y. M., de Borst, G. J., Asselbergs, F. W., van der Graaf, Y., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.09.053 · Cited by 26
Gissler, M. C., Scherrer, P., Anto-Michel, N., Pennig, J., Hoppe, N., Füner, L., Härdtner, C., Stachon, P., Li, X., Mitre, L. S., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1397-1858 · Cited by 26
Corrales‐Medina, V., deKemp, R. A., Chirinos, J. A., Zeng, W., Wang, J., WATERER, G. W., Beanlands, R. S., & Dwivedi, G. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.02.048 · Cited by 24
Feinstein, M. J., Doyle, M. F., Stein, J. H., Sitlani, C. M., Fohner, A. E., Huber, S. A., LANDAY, A. L., Heckbert, S. R., Rice, K. M., Kronmal, R. A., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315886 · Cited by 22
Tejera, C. H., Minnier, J., Fazio, S., Safford, M. M., Colantonio, L. D., Irvin, M. R., Howard, V. J., Zakai, N. A., & Pamir, N. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100198 · Cited by 21
Calcium pyrophosphate deposition (CPPD) disease – Treatment options
Stack, J. R., & McCarthy, G. (2021) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2021.101720 · Cited by 23
Shi, J., Weng, J., & Mitchison, T. J. (2021) · eLife · doi:10.7554/elife.73673 · Cited by 32
“It is still widely prescribed as a pure molecule for treating gout, Familial Mediterranean Fever and other inflammatory diseases and is being actively explored as a preventive in cardiovascular disease (Dasgeb et al., 2018; Tardif et al., 2019; Cocco et al., 2010).”
BackgroundWu, X., Xu, M., Liu, Z., Zhang, Z., Liu, Y., Luo, S., Zheng, X., Little, P. J., Xu, S., & Weng, J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106043 · Cited by 23
Nadel, J., Jabbour, A., & Stocker, R. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac081 · Cited by 26
Inflammation, Lymphatics, and Cardiovascular Disease: Amplification by Chronic Kidney Disease
Kon, V., Shelton, E. L., Pitzer, A. L., Yang, H., & Kirabo, A. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01206-4 · Cited by 24
“The Colchicine Cardiovascular Outcomes Trial (COLCOT) tested the anti-inflammatory drug colchicine and showed significantly reduced cardiovascular events, particularly decreases in risk of stroke and angina requiring coronary revascularization [5].”
BackgroundLeisegang, K. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-89340-8_11 · Cited by 26
Cai, K., Wu, B., Mehta, S., Harwood, M. L. N., Grey, C., Dalbeth, N., Wells, S., Jackson, R., & Poppe, K. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000081 · Cited by 23
“16 Similar findings were seen in the LoDoCo2 trial.”
Wohlfahrt, P., Jenča, D., Melenovský, V., Šramko, M., Kotrč, M., Želízko, M., Mrázková, J., Adámková, V., Pitha, J. V., & Kautzner, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1051995 · Cited by 28
May, L. T., Bartolo, B. A. D., Harrison, D. G., Guzik, T. J., Drummond, G. R., Figtree, G. A., Ritchie, R. H., Rye, K., & de Haan, J. B. (2022) · Clinical Science · doi:10.1042/cs20210862 · Cited by 24
Patel, T. P., Levine, J. A., Elizondo, D. M., Arner, B. E., Jain, A., Saxena, A., Lopez-Ocasio, M. D., Dagur, P. K., Famuyiwa, O., Gupta, S., et al. (2023) · Obesity · doi:10.1002/oby.23632 · Cited by 23
“Large randomized controlled trials (RCT) have shown that colchicine-treated patients suffer fewer myocardial infarction, stroke, and composite cardiovascular disease outcomes than placebo-treated patients [8-10].”
BackgroundAlam, M., Kontopantelis, E., Mamas, M. A., Savinova, O. V., Jhaveri, A., Siddiqui, E., & Jhamnani, S. (2023) · Coronary Artery Disease · doi:10.1097/mca.0000000000001220 · Cited by 26
The Effect of Colchicine on Atrial Fibrillation: A Systematic Review and Meta-Analysis
Kommu, S., & Arepally, S. (2023) · Cureus · doi:10.7759/cureus.35120 · Cited by 34
“, 2019 [23]; LODOCO2 - study by Nidorf et al.”
BackgroundInfluentialGurgoglione, F. L., Denegri, A., Russo, M., Calvieri, C., Benatti, G., & Niccoli, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065155 · Cited by 23
“N pts a Duration Drug Clinical Composite Endpoint p Value LoDoCo [114] 532 36 m ** Colchicine 0.5 mg 0.33; CI 0.18 to 0.59 <0.001 LoDoCo2 [115] 5522 28 m ** Colchicine 0.5 mg 0.69; CI 0.57 to 0.83 <0.001 COLCOT [116] 4745 22 m ** Colchicine 0.5 mg 0.77; CI 0.71 to 0.96 0.02 COCOMO-ACS [118] 64 18 m Colchicine 0.5 mg N…”
InfluentialEffects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes
Reppo, I., Jakobson, M., & Volke, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065714 · Cited by 24
“Still, the drug did not change hsCRP or leukocyte counts in these patients [36].”
BackgroundRoddy, E., Bajpai, R. C., Forrester, H., Partington, R. J., Mallen, C. D., Clarson, L. E., Padmanabhan, N., Whittle, R., & Müller, S. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224154 · Cited by 33
Nattokinase attenuates endothelial inflammation through the activation of SRF and THBS1
Chiu, H., Chou, C., Lee, K.-T., Shih, C.-C., Huang, T.-H., & Sung, L. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131779 · Cited by 24
A MicroRNA Signature in Acute Coronary Syndrome Patients and Modulation by Colchicine
Barraclough, J., Joglekar, M. V., Januszewski, A. S., Martínez, G., Celermajer, D. S., KEECH, A. C., Hardikar, A. A., & Patel, S. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420922793 · Cited by 25
Colchicine for the treatment of coronary artery disease
Aimo, A., Pascual-Figal, D. A., Barison, A., Cediel, G., Vicente, Á. H., Saccaro, L. F., Emdin, M., & Bayés‐Genís, A. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.10.007 · Cited by 29
Poledniczek, M., Neumayer, C., Kopp, C. W., Schlager, O., Gremmel, T., Józkowicz, A., Gschwandtner, M. E., Koppensteiner, R., & Wadowski, P. P. (2023) · Biomedicines · doi:10.3390/biomedicines11082284 · Cited by 29
Fabritz, L., Chua, W., Cardoso, V. R., Al-Taie, C., Borof, K., Suling, A. I., Krause, L., Kany, S., Magnussen, C., Wegscheider, K., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae067 · Cited by 24
Ghafoury, R., Malek, M., Ismail‐Beigi, F., & Khamseh, M. E. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01743-6 · Cited by 31
“While these results are encouraging, further large‑scale studies are required to solidify the role of IL‑1 inhibitors in HF treatment [45, 46, 68, 69].”
Taylor, E. B., Hall, J. E., & Mouton, A. J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107761 · Cited by 29
Cardiovascular inflammaging: Mechanisms, consequences, and therapeutic perspectives
Spray, L., Richardson, G. D., Haendeler, J., Altschmied, J., Rumampouw, V., Wallis, S. B., Georgiopoulos, G. A., White, S. J., Unsworth, A. J., Stellos, K., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102264 · Cited by 36
“Three seminal randomised controlled trials—CANTOS, 160 the Colchicine Cardiovascular Outcomes Trial (COLCOT), 161 and the The Low-dose Colchicine 2 (LoDoCo2) 162 —have demonstrated the efficacy of targeting inflammation for secondary prevention of CV events.”
Review of Current Management of Myocardial Infarction
Saha, T., & Soliman-Aboumarie, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176241 · Cited by 35
“However, there is a noted increase in non-cardiovascular mortality [54,55].”
Cellular Senescence, Inflammaging and Cardiovascular Disease
Zanders, L., Arifaj, D., Wagner, J. U. G., & Dimmeler, S. (2026) · Immunological Reviews · doi:10.1111/imr.70084 · Cited by 33
“Later trials showed benefits of colchicine treatment, an immuno-modulatory drug primarily exerting anti-inflammatory effects through NLRP3 inhibition, in chronic coronary syndromes and post-AMI [186, 187].”
Kim, E. J., & Wierzbicki, A. S. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320924569 · Cited by 22
Penson, P. E., & Banach, M. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00887-z · Cited by 26
Pathophysiologic mechanisms of cerebral endotheliopathy and stroke due to Sars-CoV-2
Kakarla, V., Kaneko, N., Nour, M., Khatibi, K., Elahi, F. M., Liebeskind, D. S., & Hinman, J. D. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20985666 · Cited by 23
“The antigout medication, colchicine can also reduce IL-6 levels and may have benefit in treating cardiovascular disease including reducing ischemic stroke rates.(105) Because of this IL-6 lowering effect, colchicine has also entered clinical testing in severe Sars-CoV-2 infection.”
BackgroundBresson, D., Roubille, F., Prieur, C., Bière, L., Ivanés, F., Bouleti, C., Dubreuil, O., Rioufol, G., Boutitie, F., Sideris, G., et al. (2021) · Cardiology · doi:10.1159/000512772 · Cited by 22
Self-citationMolecular imaging of cardiovascular inflammation
MacRitchie, N. A., Noonan, J. E., Guzik, T. J., & Maffia, P. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15654 · Cited by 21
Inflammation and ischemic heart disease: The next therapeutic target?
Vilela, E., & Fontes‐Carvalho, R. (2021) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repc.2021.02.011 · Cited by 27
The role and transformative potential of IL-19 in atherosclerosis
Chen, W., Xing, J., Liu, X., Wang, S., & Xing, D. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.09.001 · Cited by 24
Factor H-related protein 1 (FHR-1) is associated with atherosclerotic cardiovascular disease
Irmscher, S., Zipfel, S. L. H., Halder, L. D., Ivanov, L., Gonzalez‐Delgado, A., Waldeyer, C., Seiffert, M., Brunner, F. J., von der Heide, M., Löschmann, I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-02011-w · Cited by 25
Metabolomics of Arterial Stiffness
Paapstel, K., & Kals, J. (2022) · Metabolites · doi:10.3390/metabo12050370 · Cited by 25
“Recent large-scale RCTs have partially addressed residual inflammatory CV risk by targeting tubuline polymerization [1,2] and neutralizing interleukin-1β [3] and interleukin-6 [4].”
BackgroundTufaro, V., Serruys, P. W. J. C., Räber, L., Bennett, M. R., Torii, R., Gu, S. Z., Onuma, Y., Mathur, A., Baumbach, A., & Bourantas, C. V. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac051 · Cited by 23
The Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease
Bornfeldt, K. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317163 · Cited by 23
Silverio, A., Cancro, F. P., Esposito, L., Bellino, M., D’Elia, D., Verdoia, M., Vassallo, M. G., Ciccarelli, M., Vecchione, C., Galasso, G., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062161 · Cited by 33
“Anti-inflammatory therapies have been proposed as potential game changers in the future management of patients with established ASCVD, and NLRP3 inflammasome and its products could be targets for future drugs.”
BackgroundInfluentialPark, C. S., Yang, H., Han, K., Lee, H., Kang, J., Han, J., Park, K. W., Kang, H., Koo, B., & Kim, H.-S. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.05.003 · Cited by 26
The Prognostic Value of the Triglyceride Glucose Index in Patients With Acute Myocardial Infarction
Hao, Q., Yuanyuan, Z., & Lijuan, C. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231181846 · Cited by 24
HDAC9 Inhibition as a Novel Treatment for Stroke
Markus, H. S. (2023) · Stroke · doi:10.1161/strokeaha.123.044862 · Cited by 24
Delivery Strategies for Colchicine as a Critical Dose Drug: Reducing Toxicity and Enhancing Efficacy
Lei, Y., Yang, Y., Yang, G., Li, A., Yang, Y., Wang, Y., & Gao, C. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020222 · Cited by 23
“In addition, a recent large-scale clinical study confirmed that low-dose COL significantly reduced the risk of ischemic cardiovascular events in patients with recent myocardial infarction [101].”
BackgroundAkl, E., Sahami, N., Labos, C., Genest, J. J., Zgheib, A., Piazza, N., & Jolly, S. S. (2024) · Journal of Interventional Cardiology · doi:10.1155/2024/8646351 · Cited by 27
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023
Tamargo, J. L., Agewall, S., Borghi, C., Ceconi, C., Cerbai, E., Dan, G. A., Ferdinándy, P., Grove, E. L., Rocca, B., Magavern, E. F., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae013 · Cited by 27
“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”
Punnanithinont, N., Kambalapalli, S., Iskander, B., Ichikawa, K., Krishnan, S., Lakshmanan, S., Roy, S. K., & Budoff, M. J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01267-7 · Cited by 24
“…to secondary prevention, according to the Colchicine Cardiovascular Outcomes Trial (COLCOT), the result showed a significant 23% risk reduction in ischemic cardiovascular events (HR 0.77, 95% CI 0.61–0.96, p = 0.02) in patients in colchicine group who had a recent MI within 30 days [32, 33].”
InfluentialHays, A. G., Schär, M., Barditch‐Crovo, P., Bagchi, S., Bonanno, G., Meyer, J., Afework, Y., Streeb, V., Stradley, S., Kelly, S., et al. (2021) · AIDS · doi:10.1097/qad.0000000000002845 · Cited by 23
“placebo and reported a reduction in a composite endpoint of CV events driven by reduced incidence of stroke and hospitalization for angina in the LDC group [27].”
BackgroundSamuel, M., & Tardif, J. (2021) · Future Cardiology · doi:10.2217/fca-2021-0027 · Cited by 23
Self-citationAdipose tissue lymphocytes and obesity
Gao, F., Litchfield, B. A., & Wu, H.-Z. (2023) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.38 · Cited by 24
The Evolving Role of Dendritic Cells in Atherosclerosis
Britsch, S., Langer, H. F., Duerschmied, D., & Becher, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042450 · Cited by 26
Mohammadnia, N., van Broekhoven, A., Bax, W. A., Eikelboom, J. W., Mosterd, A., Fiolet, A. T. L., Tijssen, J. G. P., Thompson, P. L., de Kleijn, D. P. V., Tsimikas, S., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae355 · Cited by 24
Papadopoulos, C. E., Patoulias, D., Teperikidis, E., Mouselimis, D., Tsarouchas, A., Toumpourleka, M., Boulmpou, A., Bakogiannis, C., Doumas, M. N., & Vassilikos, V. P. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00421-x · Cited by 23
Wudexi, I., Shokri, E., Abo-Aly, M. A., Shindo, K., & Abdel‐Latif, A. (2021) · Mediators of Inflammation · doi:10.1155/2021/5160728 · Cited by 22
“After title and abstract screening and full-text review, nineteen trials including 70,620 patients met our inclusion criteria utilizing the following medications: pexelizumab (6 studies) [16, 28–32], anakinra (3 studies) [33–35], colchicine (2 studies) [36, 37], darapladib (2 studies) [38, 39], varespladib (2 studies)…”
BackgroundMethodResultInfluentialIncomplete Recovery From Takotsubo Syndrome Is a Major Determinant of Cardiovascular Mortality
Matsushita, K., Lachmet-Thébaud, L., Marchandot, B., Trimaille, A., Sato, C., Dagrenat, C., Gréciano, S., de Poli, F., Leddet, P., Peillex, M., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-1116 · Cited by 21
Hofbauer, T. M., Mangold, A., Ondracek, A. S., Panzenboeck, A., Scherz, T., Müller, J., Distelmaier, K., Seidl, V., Kastl, S., Müller‐Nurasyid, M., et al. (2021) · Basic Research in Cardiology · doi:10.1007/s00395-021-00864-w · Cited by 24
“Recent large-scale studies employing colchicine, an inhibitor of NET formation [41] lowering event rates after MI [44] and in chronic coronary artery disease [37] lend support to this idea.”
BackgroundAnti-inflammatory and Immunomodulatory Therapies in Atherosclerosis
Deroissart, J., Porsch, F., Köller, T., & Binder, C. J. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_505 · Cited by 28
“Another recent double-blind randomized placebo-controlled colchicine intervention study, named COLCOT (colchicine cardiovascular outcomes trial), aimed to assess the benefit of colchicine in patients with a recent acute MI (Tardif et al. 2019).”
BackgroundCausal Associations of Urate With Cardiovascular Risk Factors: Two-Sample Mendelian Randomization
Lukkunaprasit, T., Rattanasiri, S., Ongphiphadhanakul, B., McKay, G. J., Attia, J. R., & Thakkinstian, A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.687279 · Cited by 21
Repurposing Colchicine for Heart Disease
Bouabdallaoui, N., & Tardif, J. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-020445 · Cited by 23
Self-citationColchicine — From rheumatology to the new kid on the block: Coronary syndromes and COVID-19
Surma, S., Basiak, M., Romańczyk, M., Filipiak, K. J., & Okopień, B. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0123 · Cited by 21
“[29], involving 4745 patients recruited within 30 days of MI, assessed the efficacy of colchicine in secondary cardiovascular prevention.”
BackgroundInflammation as a Mechanism and Therapeutic Target in Peripheral Artery Disease
Chan, N., Xu, K., de Vries, T. A. C., Eikelboom, J. W., & Hirsh, J. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.01.026 · Cited by 24
Resolution-promoting autacoids demonstrate promising cardioprotective effects against heart diseases
Hiram, R. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07230-6 · Cited by 24
Metadata
- Authors
- Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., Berry, C., López-Sendón, J., Ostadal, P., Koenig, W., Angoulvant, D., Grégoire, J. C., Lavoie, M.-A., Dubé, M.-P., Rhainds, D., Provencher, M., Blondeau, L., Orfanos, A., L’Allier, P. L., Guertin, M.-C., & Roubille, F.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- From the Montreal Heart Institute (J.-C.T., R.I., J.C.G., M.-A.L., M.-P.D., D.R., P.L.L.) and the Montreal Health Innovations Coordinating Center (M.P., L.B., A.O., M.-C.G.), Montreal, Centre Hospitalier Régional de Lanaudière, Joliette (S.K.), and Institut de Cardiologie et Pneumologie de Québec, Quebec City (O.F.B.) — all in Canada; San Francisco General Hospital, San Francisco (D.D.W.); Estudios Clínicos Latinoamérica, Rosario, Argentina (R.D.); Associazione Nazionale Medici Cardiologi...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-12-26
- Volume
- 381
- Issue
- 26
- Pages
- 2497-2505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2986700515
- Cited by
- 3,159
- References
- 20
- Citations by year
- 2026: 505 · 2025: 519 · 2024: 445 · 2023: 415 · 2022: 414 · 2021: 485 · 2020: 361 · 2019: 10
- FWCI
- 230.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Funders
- Government of Quebec
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- colchicine, myocardial infarction, anti-inflammatory therapy, inflammation in atherosclerosis, cardiovascular mortality, major adverse cardiovascular events, stroke, angina pectoris, diarrhea, pneumonia, drug safety, low-dose colchicine, secondary prevention, coronary revascularization, cardiac arrest, myocardial infarction recurrence, cardiovascular risk reduction, cost-effectiveness, quality of life
- MeSH terms
- Aged, Angina Pectoris, Anti-Inflammatory Agents, C-Reactive Protein, Cardiovascular Diseases, Colchicine, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Recurrence, Biomarkers, Incidence, Proportional Hazards Models, Stroke, Kaplan-Meier Estimate, Intention to Treat Analysis, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

